

CONTACT US ([HTTPS://CUREHHT.ORG/WHO-WE-ARE/CONTACT-US-2/](https://curehht.org/who-we-are/contact-us-2/))

JOIN US ([HTTPS://CUREHHT.ORG/GET-INVOLVED/STAY-IN-TOUCH/](https://curehht.org/get-involved/stay-in-touch/))

CUREHHT CANADA ([HTTPS://HHTCANADA.COM/](https://hhtcanada.com/))


RESEARCH HUB ([HTTPS://HUB.CUREHHT.ORG/](https://hub.curehht.org/)) [DONATE](https://curehht.org/donate/) ([HTTPS://CUREHHT.ORG/DONATE/](https://curehht.org/donate/))

Search



Called *to* Cure

GENERATION TO END HHT



*Learn
About
Our
Progress*

(<https://curehht.org/called-cure/>)

READ OUR UPDATED POLICY STATEMENT:

Iron Replacement
in HHT

(<https://curehht.org/resource/policy-statement-iron-replacement-in-hht/>)

A MAJOR STEP FOR

HHT TREATMENT

NEW RESEARCH SHOWS A POTENTIAL
THERAPY MAY REVERSE AVMs—
REDUCING THE NEED FOR SURGERY AND
TARGETING THE ROOT CAUSE OF HHT.

(<https://curehht.org/a-major-step-forward-for-hht-treatment-promising-preclinical-data-from-diagnosed-for-hht-patients/>)



A HISTORY OF PAZOPANIB

There are no FDA-approved therapeutics for the treatment of HHT. **Cure HHT sought to change that.**

In many ways, the history of pazopanib is not unlike the story of the HHT community. Both are defined by persistence: a long battle for awareness, funding, and ultimately, solutions. Now, after years of dedicated effort, the paths of pazopanib and HHT have converged, moving forward in unison and resulting in the accomplishment of a pazopanib clinical trial filling and closing to enrollment. This is a major step forward for the future of HHT treatment, as we push to bring our community FDA-approved therapies for the first time.

READ MORE ([HTTPS://CUREHHT.ORG/A-HISTORY-OF-PAZOPANIB/](https://curehht.org/a-history-of-pazopanib/))

(<https://curehht.org/understanding-hht/what-is-hht/>)



What is HHT (<https://curehht.org/understanding-hht/what-is-hht/>)

HHT affects more than 1.4 million people worldwide and is the 2nd most common genetic bleeding disorder in the U.S. But it is still often misdiagnosed and misunderstood.

(<https://curehht.org/who-we-are/our-impact/>)



What We've Accomplished (<https://curehht.org/who-we-are/our-impact/>)

Since our inception in 1991, we've worked tirelessly to raise awareness, improve treatments, and increase patient access to life-saving care.

(<https://curehht.org/research/>)



Research (<https://curehht.org/research/>)

Research is the key to our future – we fund and drive scientific research to better the lives of HHT patients everywhere.

(<https://curehht.org/get-involved/>)



Join Us (<https://curehht.org/get-involved/>)

By joining our community, you ensure you're the first to know about the latest HHT news, research, advancements and more.

Impact by the numbers.

We drive science forward through government advocacy, seed grants, and other means. Turning your donations into millions of dollars dedicated to funding new treatments, technology, and drugs.

\$0n	\$0n	0%
invested	in	return on
in	leveraged	investme
28 seed	investme	nt
grants	nt	

Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu Syndrome, is an inherited disease that leads to malformed blood



vessels in multiple organs of the body and typically begins with nosebleeds during childhood. HHT can result in serious health problems if not promptly diagnosed and treated. Our mission is to find a cure for HHT while saving the lives and improving the well-being of individuals and families affected by HHT.

LEARN MORE
([HTTPS://CUREHHT.ORG/UNDERSTANDING-HHT/](https://curehht.org/understanding-hht/))

The Latest

(<https://curehht.org/2025-hht-patient-and-physician-national-conference/>)

2025 HHT Patient and Physician National Conference
(<https://curehht.org/2025-hht-patient-and-physician-national-conference/>)

(<https://curehht.org/cure-hht-leads-global-breakthrough-in-bleeding-standards-paving-the-way-for-future-hht-therapies/>)

Cure HHT Leads Global Breakthrough in Bleeding Standards, Paving the Way for Future HHT Therapies
(<https://curehht.org/cure-hht-leads-global-breakthrough-in-bleeding-standards-paving-the-way-for-future-hht-therapies/>)

(<https://curehht.org/this-landmark-hht-study-could-shift-national-attention/>)

Shift National Attention
(<https://curehht.org/this-landmark-hht-study-could-shift-national-attention/>)

(<https://curehht.org/a-major-step-forward-for-hht-treatment-promising-preclinical-data-from-diagonal-therapeutics/>)

A Major Step Forward for HHT Treatment Promising Preclinical Data from Diagonal Therapeutics
(<https://curehht.org/a-major-step-forward-for-hht-treatment-promising-preclinical-data-from-diagonal-therapeutics/>)

MORE NEWS ([HTTPS://CUREHHT.ORG/NEWS-RESOURCES/LATEST-NEWS/](https://curehht.org/news-resources/latest-news/))

1 in 0

Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder of the blood vessels that affects approximately 1 in 5,000 people worldwide.

0%

of people with HHT are undiagnosed

HHT News You Can Use

Receive updates direct to your inbox.

NEWSLETTER SIGNUP

"*" indicates required fields

<input type="text" value="First Name"/>	<input type="text" value="Last Name"/>	<input type="text" value="I have HHT"/>	<input type="button" value="JOIN"/>
<input type="text" value="Enter your email"/>	<input type="text" value="United States"/>		

If you have previously unsubscribed from receiving our emails and would like to be re-added, click here (<http://eepurl.com/c7qGuf>).



2025 © Cure HHT.
All Rights Reserved
Privacy Policy
(<https://curehht.org/privacy-policy-2/>) |
Terms of Use
(<https://curehht.org/website-disclaimer/>)

2025 © Copyright
HHT Foundation
International, Inc.

Cure
HHT

P.O. Box
329

Monkton, MD
21111
USA

501(c)(3)
Nonprofit
Organization
TAX ID
#22-
3115041

Send us an
email >>

(<https://curehht.org/who-we-are/contact-us-2/>)

P: 410-357-
9932

F: 410-472-
5559

(410) 357-9932

(410) 472-5559

(410) 357-9932

(410) 357-9932